Evidence map›Paper›PMID 35640283›Full record

ArticleJournal of the Pediatric Infectious Diseases Society2022

Effectiveness of 7-Valent Pneumococcal Conjugate Vaccine Against Invasive Pneumococcal Disease in Medically At-Risk Children in Australia: A Record Linkage Study.

Alamgir Kabir, Anthony T Newall, Deborah Randall, Hannah C Moore, Sanjay Jayasinghe, Parveen Fathima, Bette Liu, Peter McIntyre, Heather F Gidding

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of the Pediatric Infectious Diseases Society, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.9field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 6 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

Alamgir KabirSchool of Population Health, Faculty of Medicine, University of New South Wales, Sydney, New South Wales, Australia.ORCID 0000-0002-3762-8307
Anthony T NewallSchool of Population Health, Faculty of Medicine, University of New South Wales, Sydney, New South Wales, Australia.
Deborah RandallThe University of Sydney Northern Clinical School, Sydney, New South Wales, Australia.
Hannah C MooreWesfarmers Centre of Vaccines and Infectious Diseases, Telethon Kids Institute, The University of Western Australia, Perth, Western Australia, Australia.
Sanjay JayasingheNational Centre for Immunisation Research and Surveillance, Westmead, New South Wales, Australia.
Parveen FathimaWesfarmers Centre of Vaccines and Infectious Diseases, Telethon Kids Institute, The University of Western Australia, Perth, Western Australia, Australia.
Bette LiuSchool of Population Health, Faculty of Medicine, University of New South Wales, Sydney, New South Wales, Australia.
Peter McIntyreNational Centre for Immunisation Research and Surveillance, Westmead, New South Wales, Australia.
Heather F GiddingSchool of Population Health, Faculty of Medicine, University of New South Wales, Sydney, New South Wales, Australia.
The University of Sydney · AUThe Kids Research Institute Australia · AUUNSW Sydney · AUNational Centre for Immunisation Research & Surveillance · AU

Funding

National Health and Medical Research Council APP1082342
6 · The paper itself

Abstract

backgroundChildren with chronic medical conditions are at higher risk of invasive pneumococcal disease (IPD), but little is known about the effectiveness of the primary course of pneumococcal conjugate vaccine (PCV) in these children.

methodsA cohort born in 2001-2004 from two Australian states and identified as medically at-risk (MAR) of IPD either using ICD-coded hospitalizations (with conditions of interest identified by 6 months of age) or linked perinatal data (for prematurity) were followed to age 5 years for notified IPD by serotype. We categorized fully vaccinated children as either receiving PCV dose 3 by <12 months of age or ≥1 PCV dose at ≥12 months of age. Cox proportional hazard modeling was used to estimate hazard ratios (HRs), adjusted for confounders, and vaccine effectiveness (VE) was estimated as (1-HR) × 100.

resultsA total of 9220 children with MAR conditions had 53 episodes of IPD (43 vaccine-type); 4457 (48.3%) were unvaccinated and 4246 (46.1%) were fully vaccinated, with 1371 (32.3%) receiving dose 3 by 12 months and 2875 (67.7%) having ≥1 dose at ≥12 months. Estimated VE in fully vaccinated children was 85.9% (95% CI: 33.9-97.0) against vaccine-type IPD and 71.5% (95% CI: 26.6-88.9) against all-cause IPD.

conclusionThis is the first population-based study evaluating the effectiveness of PCV in children with MAR conditions using record linkage. Our study provides evidence that the VE for vaccine-type and all-cause IPD in MAR children in Australia is high and not statistically different from previously reported estimates for the general population. This method can be replicated in other countries to evaluate VE in MAR children.

Indexed as

Pneumococcal InfectionsPneumococcal VaccinesAdultAustraliaChildChild, PreschoolHumansInfantSerogroupVaccines, ConjugateYoung AdultPneumococcal VaccinesVaccines, Conjugateinvasive pneumococcal diseasemedically at-risk conditionpneumococcal conjugate vaccinerecord linkagevaccine effectiveness

Identifiers

PMID35640283
PMCPMC9520284
OpenAlexW4282914994

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.